These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37497212)

  • 1. Current understanding of CTLA-4: from mechanism to autoimmune diseases.
    Hossen MM; Ma Y; Yin Z; Xia Y; Du J; Huang JY; Huang JJ; Zou L; Ye Z; Huang Z
    Front Immunol; 2023; 14():1198365. PubMed ID: 37497212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What did we learn from CTLA-4 insufficiency on the human immune system?
    Mitsuiki N; Schwab C; Grimbacher B
    Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.
    Kim GR; Choi JM
    Mol Cells; 2022 Aug; 45(8):513-521. PubMed ID: 35950451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 regulates T follicular regulatory cell differentiation and participates in intestinal damage caused by spontaneous autoimmunity.
    Chao G; Li X; Ji Y; Zhu Y; Li N; Zhang N; Feng Z; Niu M
    Biochem Biophys Res Commun; 2018 Nov; 505(3):865-871. PubMed ID: 30301533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female-biased incidence of experimental autoimmune encephalomyelitis reflects sexually dimorphic expression of surface CTLA-4 (CD152) on T lymphocytes.
    Luna RM; Körmendy D; Brunner-Weinzierl MC
    Gend Med; 2010 Aug; 7(4):296-308. PubMed ID: 20869630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.
    Jain N; Nguyen H; Chambers C; Kang J
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1524-8. PubMed ID: 20080649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4 expressed by FOXP3
    Klocke K; Holmdahl R; Wing K
    Immunology; 2017 Sep; 152(1):125-137. PubMed ID: 28497863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
    Wing K; Yamaguchi T; Sakaguchi S
    Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological manifestation of immune system dysregulation resulting from CTLA-4 receptor mutation: a case report.
    Kolcava J; Litzman J; Bednarik J; Stulik J; Stourac P
    Mult Scler Relat Disord; 2020 Oct; 45():102313. PubMed ID: 32623363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
    Yamaguchi T; Kishi A; Osaki M; Morikawa H; Prieto-Martin P; Wing K; Saito T; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Jun; 110(23):E2116-25. PubMed ID: 23690575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4: From mechanism to autoimmune therapy.
    Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
    Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
    Schmidt EM; Wang CJ; Ryan GA; Clough LE; Qureshi OS; Goodall M; Abbas AK; Sharpe AH; Sansom DM; Walker LS
    J Immunol; 2009 Jan; 182(1):274-82. PubMed ID: 19109158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4.
    Yang M; Klocke K; Hernandez CM; Xu B; Gjertsson I; Wing K; Holmdahl R
    Immunology; 2018 Dec; 155(4):446-457. PubMed ID: 29992549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4: a key regulatory point in the control of autoimmune disease.
    Scalapino KJ; Daikh DI
    Immunol Rev; 2008 Jun; 223():143-55. PubMed ID: 18613834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
    Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
    Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells.
    Kolar P; Hoff H; Maschmeyer P; Burmester GR; Brunner-Weinzierl MC
    Clin Exp Rheumatol; 2011; 29(2):254-60. PubMed ID: 21418778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
    Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
    Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.
    Stumpf M; Zhou X; Chikuma S; Bluestone JA
    Eur J Immunol; 2014 Jun; 44(6):1737-46. PubMed ID: 24648182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis.
    Czaja AJ
    Autoimmunity; 2019 Jun; 52(4):144-160. PubMed ID: 31298041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.